Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
N Gagelmann, A Badbaran, RB Salit… - Blood, The Journal …, 2023 - ashpublications.org
Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …
[HTML][HTML] High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an …
N Gagelmann, RB Salit, T Schroeder, A Badbaran… - …, 2022 - journals.lww.com
There is no direct evidence to recommend specific conditioning intensities in myelofibrosis
undergoing allogeneic hematopoietic cell transplantation, especially in the molecular era …
undergoing allogeneic hematopoietic cell transplantation, especially in the molecular era …
Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP
J Wachowiak, JE Galimard, A Dalissier… - Bone Marrow …, 2024 - nature.com
This retrospective study evaluated 35 children (median age 5.2 years; range 0.4–18) with
myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary …
myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary …
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by …
VWK Li, R Yim, P Lee, L Chin, L Au, GMK Leung… - Annals of …, 2023 - Springer
Relapse after allogeneic haematopoietic stem cell transplantation (HSCT) is one of the key
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …
Allogeneic HSCT for classical BCR:: ABL1-negative myeloproliferative neoplasms in children: the retrospective study of the EBMT Pediatric Diseases WP
J Wachowiak, JE Galimard, A Dalissier, R Rihani… - 2023 - researchsquare.com
This retrospective EBMT registry-based study evaluated 42 children (0.4–18 years, median
6.1) with BCR:: ABL1-neg MPN (PMF, n= 33; ET, n= 3; PV, n= 1, sAML, 3; post-ET/PV-MF, n …
6.1) with BCR:: ABL1-neg MPN (PMF, n= 33; ET, n= 3; PV, n= 1, sAML, 3; post-ET/PV-MF, n …